Growth differentiating factor-15 and its association with traditional cardiovascular risk factors: The African-PREDICT study

Vermeulen, Bridget; Schutte, Aletta E.; Gafane-Matemane, Lebo F.; Kruger, Ruan

doi:10.1016/j.numecd.2020.03.001

Cited by 8 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to other established CVD biomarkers, GDF-15 is also strongly related to numerous non-cardiovascular conditions such as kidney diseases, diabetes mellitus, neoplasia and cancer-induced anorexia, or rheumatoid arthritis [ 17 , 18 ]. Even in young subjects without overt CVD, GDF-15 might represent an early indicator of CV risk development [ 21 ]. Finally, its strong association with all-cause mortality [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ] might also imply a crucial role of GDF-15 in biological processes associated with ageing.…”

Section: Introductionmentioning

confidence: 99%

Growth Differentiation Factor-15 as a Potent Predictor of Long-Term Mortality among Subjects with Osteoarthritis

Arnold

Rehm

Büchele

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Subjects with osteoarthritis (OA) are at increased risk for cardiovascular (CV) and all-cause mortality. Whether biomarkers improve outcome prediction in these patients remains to be elucidated. We investigated the association between growth differentiation factor 15 (GDF-15), a novel stress-responsive cytokine, and long-term all-cause mortality among OA patients. Methods: Within the Ulm Osteoarthritis Study, GDF-15 has been measured in the serum of 636 subjects, who underwent hip or knee arthroplasty between 1995 and 1996 (median age 65 years). Results: During a median follow-up of 19.7 years, a total of 402 deaths occurred. GDF-15 was inversely associated with walking distance. Compared to the bottom quartile (Q), subjects within the top quartile of GDF-15 demonstrated a 2.69-fold increased risk of dying (hazard ratio (HR) (95% confidence interval (CI)) 2.69 (1.82–3.96) adjusted for age, sex, BMI, smoking status, localization of OA, diabetes, maximum walking distance, total cholesterol, and cystatin C. Further adjustment for NT-proBNP, troponin I, and hs-C-reactive protein did not change the results appreciably (HR (95%CI) 1.56 (1.07–2.28); 1.75 (1.21–2.55); 2.32 (1.55–3.47) for Q2, Q3, and Q4 respectively, p for trend < 0.001). Conclusions: In subjects with OA, GDF-15 represents a potent predictor of decreased survival over >20 years, independently of conventional CV risk factors, renal, cardiac, and inflammatory biomarkers as well as walking disability, previously associated with increased mortality and lower extremity OA.

show abstract

Section: Introductionmentioning

confidence: 99%

Growth Differentiation Factor-15 as a Potent Predictor of Long-Term Mortality among Subjects with Osteoarthritis

Arnold

Rehm

Büchele

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…In a recent cross‐sectional study, Carballo‐Casla et al found that in older Spanish adults without diabetes and CVD, higher GDF‐15 levels were significantly associated with MetS, as well as high waist circumference, elevated glucose levels, and low high‐density lipoprotein cholesterol (HDL‐C) 7 . In addition, several observational studies reported the GDF‐15 levels were positively associated with age 8–12 . Similarly, Eggers et al found in elderly participants from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study that GDF‐15 levels increased significantly by 11% over 5 years 13 .…”

Section: Introductionmentioning

confidence: 94%

Growth differentiation factor‐15 is independently associated with metabolic syndrome and hyperglycemia in non‐elderly subjects

Hung

et al. 2022

BioFactors

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is a major health issue worldwide accompanied by cardiovascular comorbidities. Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine expressed in cardiomyocytes, adipocytes, macrophages, and endothelial cells. Previous research in elderly subjects revealed that GDF-15 levels were associated with the MetS. However, the association between GDF-15 levels and MetS or its components in the non-elderly subjects remains unclear. In this study, a total of 279 subjects younger than 65-year-old with (n = 84) or without (n = 195) MetS were recruited. MetS was defined according to modified NCEP/ATP III criteria. The GDF-15 levels were measured by an enzyme-linked immunosorbent assay. A multiple linear regression analysis was conducted to identify factors independently associated with GDF-15 levels. Subjects with MetS had higher GDF-15 levels than those without MetS (median (interquartile range), 1.72 ng/mL (1.38, 2.26) vs. 1.63 ng/mL (1.27, 2.07), P = 0.037). With the number of MetS components increased, the GDF-15 levels increased significantly (P for trend = 0.005). Multiple linear regression analysis revealed that the presence of MetS was positively associated with the GDF-15 levels (β = 0.132, P = 0.037). When substituting MetS with its components, only the presence of hyperglycemia was positively associated with the GDF-15 levels after adjustment for covariates (β = 0.193, P = 0.003).

show abstract

“… 11 Endothelial dysfunction plays an important role in the pathogenesis of depression, suggesting that GDF‐15 may be involved in the pathways affecting PSD. 12 GDF‐15 has also been reported to be associated with chronic vascular brain injuries 13 and central systolic BP, 14 both of which are associated with depression. 9 Further functional studies and epidemiology studies are needed to clarify the detailed mechanisms of the association between GDF‐15 and PSD.…”

Section: Discussionmentioning

confidence: 99%

Serum Growth Differentiation Factor 15 Levels Are Associated With Depression After Ischemic Stroke

Zang

Zhu

Xie

et al. 2022

JAHA

View full text Add to dashboard Cite

Background The effect of serum growth differentiation factor 15 (GDF‐15) on poststroke depression (PSD) remains unknown. This study aimed to investigate the association between serum GDF‐15 and PSD among patients with ischemic stroke. Methods and Results This study was based on a random sample from CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). A total of 572 patients from 7 participating hospitals with GDF‐15 levels were included in this analysis. The study outcome was depression (Hamilton Depression Rating Scale score ≥8) at 3 months after ischemic stroke. A total of 231 (40.4%) patients with stroke experienced PSD within 3 months. The multivariate‐adjusted odds ratio of PSD associated with the highest tertile of serum GDF‐15 was 2.92 (95% CI, 1.36–6.27) compared with the lowest tertile. Each SD increase in log‐transformed GDF‐15 was associated with a 42% (95% CI, 2%–97%) increased risk of PSD, and a linear association between serum GDF‐15 and the risk of PSD was observed ( P for linearity=0.006). Conclusions Elevated serum GDF‐15 levels in the acute phase of ischemic stroke were independently associated with PSD, suggesting that GDF‐15 may be a valuable prognostic biomarker for PSD.

show abstract

Growth differentiating factor-15 and its association with traditional cardiovascular risk factors: The African-PREDICT study

Cited by 8 publications

References 30 publications

Growth Differentiation Factor-15 as a Potent Predictor of Long-Term Mortality among Subjects with Osteoarthritis

Growth Differentiation Factor-15 as a Potent Predictor of Long-Term Mortality among Subjects with Osteoarthritis

Growth differentiation factor‐15 is independently associated with metabolic syndrome and hyperglycemia in non‐elderly subjects

Serum Growth Differentiation Factor 15 Levels Are Associated With Depression After Ischemic Stroke

Contact Info

Product

Resources

About